Alexion Pharma (ALXN) Tops Q4 EPS by 1c; Guides Below the Street, $1B Buyback Plan
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- Wall St futures tick higher as oil retreats ahead of inflation data
- Oil slips on weaker demand outlook and higher US stocks amid supply disruptions
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- Four key things investors will watch in Nvidia's earnings next week
- Silver could surge to $90 as investment demand takes over, Citi says
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Alexion Pharmaceuticals (ALXN) PT Lowered to $158 at BMO Capital Citing Competition for PNH
February 17, 2017 6:54 AM ESTBMO Capital Markets analyst M. Ian Somaiya reiterates Outperform rating, lowers price target on Alexion Pharmaceuticals (NASDAQ: ALXN) to $158 (from $166), suggesting the market has missed the impact of competition on the companys PNH franchise, despite managements positive 2017 outlook for Solaris.
Somaiya... More
Alexion Pharma (ALXN) Plans to Be 'Very Active' on Deal Opportunities
February 16, 2017 11:11 AM ESTOn its call, Alexion Pharma (NASDAQ: ALXN) said it will be very active in deal makings
".. very active from a Business Development perspective to identify opportunities that we think fit with our model and with our strategy and bring them in... More
Alexion Pharma (ALXN) interim CEO says prior guidance for 2018 cannot be relied on
February 16, 2017 10:51 AM ESTOn call, Alexion Pharma (NASDAQ: ALXN) interim CEO says prior guidance for 2018 cannot be relied on but too early for new projections.
... More